- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Gufic Biosciences appoints Rajesh Kaul as Senior President - Sparsh Cluster

Gujarat: Gufic Biosciences has announced the appointment of Rajesh Kaul as Senior President - Sparsh Cluster, Senior Management Personnel of the Company with effect from July 04, 2025.
"We wish to inform you that on the basis of recommendation of Nomination & Remuneration Committee, the Board of Directors vide Circular Resolution passed today i.e. July 02, 2025 has approved the appointment of Mr. Rajesh Kaul as Senior President – Sparsh Cluster, Senior Management Personnel of the Company with effect from July 04, 2025," the Company informed in a recent filing to BSE.
With over three decades of vast experience in pharmaceutical industry, he has been instrumental in building robust brands across Critical Care, Corporate Hospitals, Government institutions and penetrated competitive markets with strategic finesse. He is skilled in scientific brand promotion and leadership development. Kaul has successfully led large‐scale operations and driven exponential business growth across India’s highly competitive healthcare landscape.
He has held senior leadership positions at several leading pharmaceutical companies, including Mankind Pharma Limited, Zydus Healthcare Limited, Aristo Pharmaceuticals, Alkem Laboratories Limited, Wockhardt Limited and Sun Pharmaceuticals Limited.
His responsibilities have spanned strategic P&L management for portfolios exceeding Rs 500 crore, along with oversight of over 400 professionals across sales, marketing, and business development functions. Kaul has a proven track record of scaling operations from ground zero to over Rs 300 crore, consistently achieving multi‐crore growth through effective market penetration, brand development, and operational excellence.
He has played a pivotal role in the launch of multiple high‐ impact brands such as Meroza, Germero, Aggramed, Swich, and Azetrohigh—each making a mark in the critical care segment. Renowned for his strategic foresight and executional strength, Kaul has transformed underperforming regions into profitable zones, successfully entered high‐value corporate hospital chains, and repeatedly surpassed performance targets. His core expertise includes scientific brand promotion, Key Opinion Leader (KOL) engagement, institutional and government business development, and high‐impact leadership and capability building.
Rajesh Kaul holds a Bachelor degree in Science and has done Management Program from Indian Institute of Management (IIM), Kozhikode and Finance Certification from Indian Institute of Management (IIM), Ahmedabad.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751